ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 327 filers reported holding ROYALTY PHARMA PLC in Q1 2023. The put-call ratio across all filers is 0.47 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,270,443 | -21.5% | 1,668,034 | -11.0% | 0.02% | -17.9% |
| Q2 2023 | $57,644,478 | +78369.5% | 1,875,227 | -8.0% | 0.03% | -33.3% |
| Q1 2023 | $73,461 | +88.8% | 2,038,882 | +107.1% | 0.04% | +90.9% |
| Q4 2022 | $38,902 | -98.4% | 984,366 | +1516.8% | 0.02% | +2100.0% |
| Q3 2022 | $2,446,000 | -78.1% | 60,885 | -77.1% | 0.00% | -83.3% |
| Q2 2022 | $11,179,000 | +107.4% | 265,906 | +92.2% | 0.01% | +100.0% |
| Q1 2022 | $5,391,000 | +312.8% | 138,369 | +322.2% | 0.00% | +200.0% |
| Q4 2021 | $1,306,000 | -96.1% | 32,770 | -96.4% | 0.00% | -95.0% |
| Q3 2021 | $33,292,000 | -9.7% | 921,184 | +2.4% | 0.02% | -13.0% |
| Q2 2021 | $36,859,000 | +322.5% | 899,200 | +349.6% | 0.02% | +283.3% |
| Q1 2021 | $8,725,000 | +376.3% | 200,019 | +359.2% | 0.01% | +200.0% |
| Q3 2020 | $1,832,000 | -94.8% | 43,557 | -94.0% | 0.00% | -95.8% |
| Q2 2020 | $35,043,000 | – | 721,802 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |